Redeye maintains Optomed's valuation at EUR 13 per share after today's solid Q1 report. In the months ahead, we expect accelerated camera and software revenue growth.
ANNONS
Redeye maintains Optomed's valuation at EUR 13 per share after today's solid Q1 report. In the months ahead, we expect accelerated camera and software revenue growth.